European recommendations on the use of oral antibiotics for acne

European Journal of Dermatology

Volumn 14, Issue 6, 2004, Pages 391-399

  Dréno, Brigitte ^a   Bettoli, Vincenzo ^b   Ochsendorf, Falk ^c   Layton, Alison ^d   Mobacken, Håkan ^e   Degreef, Hugo ^f  

^a HÔTEL DIEU   (France)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d HARROGATE DISTRICT HOSPITAL   (United Kingdom)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Acne vulgaris; Oral antibiotics; Treatment recommendations

Indexed keywords

ADAPALENE; AMPICILLIN; ANTACID AGENT; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CLINDAMYCIN; COTRIMOXAZOLE; CYCLINE; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; LEVOFLOXACIN; LYMECYCLINE; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; OXYTETRACYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOID; RIFAMPICIN; SALICYLIC ACID; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM;

ACNE VULGARIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; AGITATION; ALLERGIC REACTION; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BRAIN PSEUDOTUMOR; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; HALLUCINATION; HEADACHE; HEPATITIS; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; NONHUMAN; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PHARMACOECONOMICS; PHOTOSENSITIVITY; PNEUMONIA; POLYARTERITIS NODOSA; PRACTICE GUIDELINE; PRESCRIPTION; PROPIONIBACTERIUM ACNES; PSEUDOMEMBRANOUS COLITIS; REVIEW; SEBORRHEA; SERUM SICKNESS; SIDE EFFECT; TENDINITIS; THYROIDITIS; VASCULITIS; VESTIBULAR DISORDER;

ACNE VULGARIS; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; EUROPE; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 9244226576     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Ad Hoc Committee report: systemic antibiotics for treatment of acne vulgaris: efficacy and safety. Arch Dermatol 1975; 111: 1630-6.
2. Drake LA. Guidelines for care of acne vulgaris. J Am Acad Dermatol 1990; 22: 676-80.
3. Taylor MB. Treatment of acne vulgaris. Guidelines for primary care physicians. Postgrad Med 1991; 89: 40-2, 45-7.
4. Oral treatment of acne. Presse Med 1999; 28: 2044-5.
5. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a global alliance to improve outcomes in acne J Am Acad Dermatol 2003; 49 (1 Suppl): S1-S38.
6. Thielitz A, Helmdach M, Ropke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19-27.
7. Leeming JP, Holland KT, Cunliffe WJ. The microbial colonization of inflamed acne vulgaris lesions. Br J Dermatol 1988; 18: 205-8.
8. Jappe U, Inaham E, Henwood J, Holland KT. Propionibacterium acnes and inflammation in acne; P. acnes has T-cell mitogenic activity. Br J Dermatol 2002; 146: 202-9.
9. Marples RR, McGinley KJ. Corynebacterium acnes and other anaerobic diphtheroids from human skin. J Med Microbiol 1974; 7: 349-57.
10. De Young LM, Young JM, Ballaron SJ, Spires DA, Puhvel SM. Intradermal injection of Propionibacterium acnes: a model of inflammation relevant to acne. J Invest Dermatol 1984; 83: 394-8.
11. Kirschbaum JD, Kligman AM. The pathogenic role of Corynebacterium acnes in acne vulgaris. Arch Dermatol 1963; 88: 832-3.
12. McGinley KJ, Webster GF, Ruggieri MR, Leyden JJ. Regional variations in density of cutaneous propionibacteria: correlation of Propionibacterium acnes populations with sebaceous secretion. J Clin Microbiol 1978; 12: 672-5.
13. Cove JH, Cunliffe WJ, Holland KT. Acne vulgaris: is the bacterial population size significant? Br J Dermatol 1980; 102: 277-80.
14. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Age-related changes in the resident bacterial flora of the human face. J Invest Dermatol 1975; 65: 379-81.
15. Holland KT, Holland DB, Cunliffe WJ, Cutcliffe AG. Detection of Propionibacterium acnes polypeptides which have stimulated an immune response in acne patients but not in normal individuals. Exp Dermatol 1993; 2: 12-16.
16. Holland KT, Aldana O, Bojar RA, Cunliffe WJ, Eady EA, Holland DB, et al. Prapianibacterium acnes and acne. Dermatology 1998; 196: 67-8.
17. Jappe U. Akne und Propionibakterien. Deutscher Dermatologe 2002: 583-9.
18. Ashbee HR, Muir SR, Cunliffe WJ, Ingham E. IgG subclasses specific to Staphylococcus epidermidis and Propionibacterium acnes in patients with acne vulgaris. Br J Dermatol 1997; 136: 730-3.
19. Eady EA, Cove JH. Is acne an infection of blocked pilosebaceous follicles ? Implications for antimicrobial treatment. Am J Clin Dermatol 2000; 1: 201-9.
20. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20-7.
21. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 2001; 15 Suppl 3: 51-5.
22. Meynadier J, Alirezai M. Systemic antibiotics for acne. Dermatology 1998; 196: 135-9.
23. rd ed. New York: Springer-Verlag. 2000.
24. Technote report 2001. www.ahrg.gov/clinic/evrptfiles.htm#acne.
25. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467-78.
26. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51-7.
27. Ray AJ, Donskey CJ. Clostridium difficile infection and concurrent vancomycin-resistant Enterococcus: colonization in a health care worker: case report and review of the literature. Am J Infect Control 2003; 31: 54-56.
28. Carrasco DA, Vander Straten M, Tyring SK. A review of antibiotics in dermatology. J Cut Med Surg 2002; 6: 128-50.
29. Cunliffe WJ, Aldana OL, Goulden V. Oral trimethoprim: a relatively safe and successful third-line treatment for acne vulgaris. Br J Dermatol 1999; 141: 757-8.
30. Kawada A, Aragane Y, Tezuka T. Levofloxacin is effective for inflammatory acne and achieves high levels in the lesions: an open study. Dermatology 2002; 204: 301-2.
31. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem 2003; 3: 249-82.
32. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002; 127: 269-77.
33. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 1975; 65: 382-4.
34. Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459-64.
35. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41-5.
36. Ozolins M, Eady EA, Avery A, Cunliffe WJ, Li Wan Po A, O'Neill C, et al. A randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Report for NHS study 94/48, January 2002.
37. Massing GS. Inhibition of Corynebacterium acnes lipase by tetracycline. J Invest Dermatol 1971; 56: 189-92.
38. Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol 1981; 104: 453-7.
39. Akamatsu H, Tomita T, Horio T. Effects of roxithromycin on the production of lipase and neutrophil chemotactic factor by Propionibacterium acnes. Dermatology 2002; 204: 277-80.
40. Hamilton-Miller JM. Immunopharmacology of antibiotics: direct and indirect immunomodulation of defence mechanisms. J Chemother 2001; 13: 107-11.
41. Brinkmeier T, Frosch PJ. Oral antibiotics with antiinflammatory/ immunomodulatory effects in the treatment of various dermatoses. Hautarzt 2002; 53: 456-65.
42. Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol 1999; 163: 2909-15.
43. Wales D, Woodhead M. The anti-inflammatory effects of macrolides. Thorax 1999; 54 (Suppl 2): S58-S62.
44. Van Vlem B, Vanholder R, De Paepe P, Vogelaers D, Ringoir S. Immunomodulating effects of antibiotics: literature review. Infection 1996; 24: 275-91.
45. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, et al. Anti-inflammatory activity af macrolide antibiotics. J Pharmacol Exp Trier 2000; 292: 156-63.
46. Jain A, Sangal L, Basal E, Kaushal GP, Agarwal SK. Antiinflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 2002; 8: 2.
47. Sainte-Marie I, Tenaud I, Jumbou O, Dreno B. Minocycline modulation of alpha-MSH production by keratinacytes in vitro. Acta Derm Venereol 1999; 79: 265-7.
48. Crawford WW, Crawford IP, Stoughton RB, Cornell RC. Laboratory induction and clinical occurence of combined clindamycin and erythromycin resistance in corynebacterium acnes. J Invest Dermatol 1979; 72: 187-190.
49. Eady EA, Bojar RA, Jones CE. The effects of acne treatment with combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria. Br J Dermatol 1996; 134: 107-113.
50. Bojar RA, Eady EA, Jones CE, Cunliffe WJ, Holland KT. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329-336.
51. Coates P, Adams CA, Cunliffe WJ, McGinley KT, Eady EA, Leyden JJ, et al. Does oral isotretinain prevent Propionibacterium acnes resistance? Dermatology 1997; 195 Suppl 1: 4-9; discussion 38-40.
52. Schollhammer M, Alirezai M. Étude comparative de la lymécycline (Tetralysal®), de la minocycline (Mynocine®) et de la doxycycline (Tolexine®) dans le traitement de l'acné vulgaire. Réal Thérapeut Dermato-Vénérol 1994; 42: 24-6.
53. Bossuyt L, Bosschaert J, Richert B, Cromphaut P, Mitchell T, Al Abadie M, et al. Lymecycline in the treatment of acne: an efficacious, safe and cost-effective alternative ta minacycline. Eur J Dermatol 2003; 13: 130-5.
54. Mobacken H. Oral tetracycline-treatment of acne. Rapid facial improvement, but back lesions are more difficult to treat. Lakartidningen 1993; 90: 2755-7.
55. Campo M, Zuluaga A, Escobar P, Motta A, Argote A, Jaramillo C, Rueda MJ, et al. A comparative study on the effectiveness of lymecicline and adapalene versus minocicline and adapalene in the treatment of acne vulgaris. Proceedings 20th World Congress of Dermatology. Paris, France, 1-5 July 2002: P0005.
56. Cunliffe WJ, Grosshans E, Belaich S, Meynadier J, Alirezai M, Thomas L. A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur J Dermatol 1998; 8: 161-6.
57. Dubertret L, Alirezai M, Rostain G, Lahfa M, Forsea D, Niculae BD, et al. The use of lymecycline in the treatment of moderate to severe acne vulgaris: a comparison of the efficacy and safety of two dosing regimens. Eur J Dermatol 2003; 13: 44-48.
58. Cunliffe WJ, Meynadier J, Alirezai M, George SA, Coutts I, Roseeuw DI, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003; 49: S218-26.
59. Biellerup M, Ljunggren B. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol 1994; 130: 356-60.
60. Bernier C, Dréno B. Minocycline. Ann Dermatol Venereol 2001; 128: 627-37.
61. Eichenfield AH. Minocycline and autoimmunity. Curr Opin Pediatr 1999; 11: 447-56.
62. Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupus-like syndrome in acné patients. Arch Intern Med 1999; 159: 493-7.
63. Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus. A systematic review. Dermatology 2000; 200: 223-31.
64. Garner SE, Eady EA, Popescu C, Newton J, Li wan po A. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2002; 2: CD002086.
65. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996; 134: 693-5.
66. Bachmeyer C, Cadranel JF. Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors. Dermatalogy 2002; 205: 185-6.
67. Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med 1998; 152: 1132-6.
68. Knowles SR, Shapiro L, Shear NH. Seriaus adverse reactions induced by minocycline. Arch Dermatol 1996; 132: 934-9.
69. Chiu AM, Chuenkongkaew WL, Cornblath WT, Trobe JD, Digre KB, Dotan SA, et al. Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol 1998; 126: 116-21.
70. Corona R. Minocycline in acne is still an issue. Arch Dermatol 2000; 136: 1143-5.
71. Chen SC. Cost-effectiveness analyses: a basic overview for dermatologists. J Cutan Med Surg 2001; 5: 217-22.
72. Hughes BR, Cunliffe WJ. Interactions between the oral contraceptive pill and antibiotics. Br J Dermatol 1990; 122: 717-8.
73. London BM, Lookingbill DP. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives. Arch Dermatol 1994; 130: 392-3.
74. Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell RT, Krishnarao I. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 1997; 36: 705-10.
75. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002; 46: 917-23.
76. ACOG: The use of hormonal contraception in women with coexisting medical conditions. ACOG Prac Bull 2000; 18: 1-13.
77. Layton AM, Hughes BR, Hull SM, Eady EA, Cunliffe WJ. Sebarrhoea - an indicator for poor clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992; 17: 173-5.